Literature DB >> 3903226

Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery.

H Hedlund, K E Andersson.   

Abstract

Contractant and relaxant effects of prostaglandins (PG) F2 alpha, E1 and E2, prostacyclin (PGI2), the thromboxane A2 agonist U46619 and the prostaglandin endoperoxide analogue U44069 were investigated in isolated preparations of the human corpus cavernosum, corpus spongiosum and cavernous artery. In corpus cavernosum and corpus spongiosum preparations, PGF2 alpha produced concentration-dependent contractions showing rhythmic variations in tension. The contractions were effectively relaxed by carbachol and vasoactive intestinal polypeptide. U46619, U44069 and PGI2 also contracted corpus cavernosum and corpus spongiosum strips at resting tension, U46619 being the most potent drug. PGE1 and PGE2, but not PGI2 relaxed corpus cavernosum and corpus spongiosum preparations contracted by noradrenaline (NA) and PGF2 alpha. PGE1 was the more effective agent; high concentrations of PGE2 produced contraction. In cavernous artery segments, PGF2 alpha produced concentration-dependent contractions. No oscillations in tension were observed; carbachol had no relaxant action, but VIP effectively relaxed the vessels. U46619 and U44069, but not PGI2 had contractant effects on cavernous artery segments at resting tension. PGE1 and PGI2, but not PGE2 relaxed NA contracted vessel preparations; all agents (PGE2 less effectively) relaxed PGF2 alpha contracted vessel segments. It is concluded that cavernous artery and erectile tissue proper (corpus cavernosum and corpus spongiosum) differ importantly in their reaction to various prostanoids. It cannot be excluded that products of the arachidonate cascade can be involved in the control of penile tumescence and erection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903226     DOI: 10.1016/s0022-5347(17)47704-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

Review 1.  Drugs for the treatment of impotence.

Authors:  L Garcia-Reboll; J P Mulhall; I Goldstein
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 2.  Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings.

Authors:  K E Andersson; F Holmquist
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

3.  Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.

Authors:  Eginhard Waldkirch; Stefan Uckert; Hüseyin Yildirim; Michael Sohn; Udo Jonas; Christian G Stief; Karl-Erik Andersson; Petter Hedlund
Journal:  World J Urol       Date:  2005-11-15       Impact factor: 4.226

4.  Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.

Authors:  T F Zaher
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 5.  Comparative tolerability and efficacy of treatments for impotence.

Authors:  W Meinhardt; R F Kropman; P Vermeij
Journal:  Drug Saf       Date:  1999-02       Impact factor: 5.606

6.  Health-related quality of life in men with erectile dysfunction.

Authors:  M S Litwin; R J Nied; N Dhanani
Journal:  J Gen Intern Med       Date:  1998-03       Impact factor: 5.128

Review 7.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

Review 8.  Drug-induced male sexual dysfunction. An update.

Authors:  G B Brock; T F Lue
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

9.  Nitric oxide mediates relaxation in rabbit and human corpus cavernosum smooth muscle.

Authors:  H H Knispel; C Goessl; R Beckmann
Journal:  Urol Res       Date:  1992

Review 10.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.